Literature DB >> 34110159

Structural and Dynamical Differences in the Spike Protein RBD in the SARS-CoV-2 Variants B.1.1.7 and B.1.351.

Nisha Bhattarai1, Prabin Baral1, Bernard S Gerstman1,2, Prem P Chapagain1,2.   

Abstract

The novel coronavirus (SARS-CoV-2) pandemic that started in late 2019 is responsible for hundreds of millions of cases worldwide and millions of fatalities. Though vaccines are available, the virus is mutating to form new strains among which are the variants B.1.1.7 and B.1.351 that demonstrate increased transmissivity and infectivity. In this study, we performed molecular dynamics simulations to explore the role of the mutations in the interaction of the virus spike protein receptor binding domain (RBD) with the host receptor ACE2. We find that the hydrogen bond networks are rearranged in the variants and also that new hydrogen bonds are established between the RBD and ACE2 as a result of mutations. We investigated three variants: the wild-type (WT), B.1.1.7, and B.1.351. We find that the B.1.351 variant (also known as 501Y.V2) shows larger flexibility in the RBD loop segment involving residue K484, yet the RBD-ACE2 complex shows higher stability. Mutations that allow a more flexible interface that can result in a more stable complex may be a factor contributing to the increased infectivity of the mutated variants.

Entities:  

Year:  2021        PMID: 34110159      PMCID: PMC8204914          DOI: 10.1021/acs.jpcb.1c01626

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


Introduction

The highly contagious severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a form of severe acute respiratory syndrome coronavirus (SARS) that had an outbreak in China in 2003 and causes the COVID-19 disease in a number of animal species including humans.[1−3] The first case of SARS-CoV-2 was detected in December 2019 in Wuhan, China, and a pandemic was declared in March 2020 due to its worldwide transmission. A person contracting this disease can have symptoms including fever, dry cough, headache, breathing difficulties, and pneumonia.[2−4] In January 2021, the number of SARS-CoV-2 cases surpassed 100 million worldwide with over 2 million deaths. Vaccines produced by Pfizer/BioNTech and Moderna have been authorized for emergency use in the United States after demonstrating efficacy in clinical trials.[5] Despite the progress in vaccine administration, emergence of mutated variants is raising concerns about vaccine efficacies. Notably, the viruses that emerged in the United Kingdom (B.1.1.7 lineage) and separately in South Africa (B.1.351 lineage, also known as 501Y.V2) are reported to increase the transmission of the virus and host immune evasion.[6,7] In the spike protein alone, the B.1.1.7 variant has amino acid deletions at H69, V70, and Y144 and mutations N501Y, A570D, P681H, T716I, S982A, and D1118H, while the South African variant has mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, and A701V.[8] The N501Y mutation at the receptor binding domain (RBD) that directly interacts with the human receptor ACE2, as shown in Figure , is found to be common in both of these mutants and is assumed to increase virus infectivity and transmittivity.[9] In the South African variant, mutations in the RBD (K417N, E484K, and N501Y) are thought to have functional significance.[10] The B.1.1.7 variant is reported to have a 71% higher transmission rate than the other variants.[11] The full significance of the B.1.351 variant is still unclear, and it is assumed that this lineage could be associated with increased transmissibility[10] and render current vaccines significantly less effective.[12]
Figure 1

SARS-CoV-2 spike trimers with RBD-up structure complexed with ACE2 for (a) B.1.1.7 and (b) B.1.351 variants after relaxing with molecular dynamics (MD) simulation. The mutated residues are highlighted in purple.

SARS-CoV-2 spike trimers with RBD-up structure complexed with ACE2 for (a) B.1.1.7 and (b) B.1.351 variants after relaxing with molecular dynamics (MD) simulation. The mutated residues are highlighted in purple. The occurrence of mutated variants with increased rates of virus transmission and immune evasion has raised concern about the necessity of modifying existing vaccines and treatments.[12,13] Guidance for these interventions can benefit from an understanding of changes in the molecular mechanisms of infection as a result of the mutations, which is also essential for understanding the enhanced virulence of the mutated variants. Although some of the studies have been performed with these variants,[14] the details of amino acids that play crucial roles at the RBDACE2 interface yet remain unexplored. In this study, we investigated the changes in molecular bonding patterns between the spike protein-mutated RBD and the host ACE2 for the B.1.1.7 and B.1.351 variants compared to that of the wild-type (WT). We find that the mutations have significant effects by changing the amino acids responsible for hydrogen bonding between the RBD and ACE2.

Materials and Methods

System Preparation

A fully glycosylated SARS-CoV-2 spike trimer in which one of the receptor binding domains is facing upwards and complexed with ACE2 was retrieved from the archives of the CHARMM-GUI[15,16] COVID-19 repository (PDB ID 6VSB_6VW1).[17−19] This wild-type (WT) structure contains modeled glycan chains at the glycosylated sites and has the missing residues filled with GalaxyFill.[20,21] The mutations or deletions were then introduced to this WT structure using CHARMM-GUI.[16] We prepared a total of nine independent systems: the spike trimer complexed with ACE2, spike RBDACE2 complex, and RBD-only system for each of WT, B.1.1.7, and B.1.351 variants. Residues 1–1146 were considered in the spike trimer structure and 19–614 in the ACE2 domain. Similarly, the RBD residues 330–530 were used in the RBD-only as well as for the RBDACE2 complex systems, and residues 19–614 were used in the ACE2 domain. All nine systems were set up using the CHARMM-GUI Solution Builder tool with standard parameters, including a physiological salt concentration of 0.15 M KCl.

Molecular Dynamics Simulations

All-atom, explicit solvent molecular dynamics (MD) simulations were performed using the NAMD 2.13 simulation package[22] with the Charmm36m force field.[23,24] The covalent bonds involving hydrogen atoms were constrained by using the SHAKE algorithm,[25] and the pressure was controlled using the Nose–Hoover Langevin piston method[26] with a piston decay of 25 fs and a period of 50 fs. The particle mesh Ewald method[27] was used to calculate the long-range ionic interactions, and the temperature was controlled by using the Langevin temperature coupling with a friction coefficient of 1 ps–1. Minimization and equilibration were performed with NVT (constant volume and temperature) conditions, and the production runs were performed under NPT (constant pressure and temperature) conditions at 303 K using 2 fs time steps. The RBD-only systems were run for 600 ns each, and the RBDACE2 systems were run for 200 ns each. Additional replicas of RBD-only systems were run for 300 ns. For all larger systems of spike protein trimer–ACE2 complexes (∼900 000 atoms), the production runs were limited to 50 ns each, which should be sufficient for the side-chain relaxations upon mutation but not for large-scale conformational changes. Visualization and rendering of trajectories were done with visual molecular dynamics (VMD).[28]

Dynamical Network Analysis

We used the Network Plugin in VMD[29,30] for dynamical network analysis calculations. Carma[31] and Catdcd[30] were used to calculate the covariance and correlations between interfacial amino acid pairs during an MD trajectory. To generate the amino acid community network, gncommunities[29] was employed. Using the Girvan–Newman algorithm, the time-averaged connectivity of the nodes was determined and the shortest path between the nodes for connections was also identified.[32]

Principal Component Analysis

The principal component analysis (PCA) of the Bio3D[33] software package was used to study the coordinated motions of amino acids and to understand the conformational motions of the atoms in all three systems. First, least-squares fitting is used to remove the translational and rotational motions of the proteins during the MD trajectory and the remaining motion of the protein atoms is analyzed.

Results and Discussion

The spike protein of the B.1.1.7 variant has deletions of H69, V70, and Y144 and mutations N501Y, A570D, P681H, T716I, S982A, and D1118H amino acids. Similarly, the B.1.351 variant has mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, and A701V. Figure shows the mutations (highlighted in purple) in the spike trimer complexed with ACE2 in both B.1.1.7 and B.1.351 variants. The RBD of B.1.1.7 has only one mutation N501Y, whereas B.1.351 has N501Y and additional mutations K417N and E484K. To investigate the interactions with the human host receptor ACE2 in more detail, we focused on the RBD-only as well as the RBDACE2 complexes.

Structural Changes and Flexibility of the RBD Due to Mutations

Mutations in SARS-CoV-2 genes can lead to alterations in protein structures.[34] To investigate the changes in the RBD structure and dynamics due to mutations, we performed MD simulations of the RBD-only systems, not complexed with ACE2, for the three variants: WT, B.1.1.7 with the mutation N501Y, and B.1.351 with three mutations N501Y, K417N, and E484K. Figure a–c shows the RBD for the WT, B.1.1.7, and B.1.351 variants after 600 ns simulations. To visualize the structural flexibility of the RBD of each variant, we overlapped 20 conformations, taken one frame every 25 ns of the last 500 ns trajectory, as displayed in Figure S1. We colored each of these conformations according to the residues’ root-mean-square fluctuations (rmsf), calculated for a 50 ns window that is centered at that specific frame. The overlapped structures, combined with the color gradients from blue–white–red, show that all variants have a flexible loop region (red) consisting of residues 473–489. Simulation of the B.1.351 variant shows significant structural changes in this loop region, which involves the mutation E484K, as shown in Figure c,d. This loop is an important RBD region as it is involved in binding with ACE2. To understand the conformational changes of the loop in B.1.351, we visualized the hydrogen-bonding pattern. For the B.1.351 variant, the initial hydrogen bonds break or weaken and the loop reorients (Figure S2a). In Figure S2b, we plotted the acceptor–donor distances between the important hydrogen-bond-forming residues for all three variants. The hydrogen bond Y473–Y489 remains intact for all three variants, whereas other hydrogen bonds fluctuate and differ. We superimposed five conformations of each variant from the last 500 ns (one conformation every 100 ns) and are displayed in Figure d, highlighting the flexible loop segment. To understand the flexibility of the loop region, we calculated the average root-mean-square fluctuations (rmsf) of the loop residues 480–489 for sliding windows of a width of 10 ns, with a total of 60 windows (Figure e). The average rmsf of the loop residues 480–489 shows that the residues in the B.1.351 show larger fluctuations in general. While the loop in the WT shows occasional large motion, as shown by the distance between the Cα atoms of residues 484 and 489, this motion is different in the B.1.1.7 and B.1.351 variants (Figure f). The loop in the B.1.1.7 variant shows multiple semistable states. However, the loop is quite flexible in B.1.351 (Figures e,f and S2 and Movie S1). This observation is reproduced in the 300 ns replica run, which shows even clearer differences in the flexibility (Figure S3b,d). A flexible loop in B.1.351 may allow the RBD to bind with ACE2 more easily by induced fit mechanism. To investigate the binding with ACE2, we further explored the interactions in the RBDACE2 complexes.
Figure 2

RBD structures at the end of 600 ns simulation for (a) WT, (b) B.1.1.7, and (c) B.1.351. The loop segments consisting of residues 473–489 are highlighted in blue. Mutations in the variants are labeled with red fonts. (d) Structural comparison of the five conformations of each variant, taken from the last 500 ns of the simulation (i.e., one frame every 100 ns). (e) Root-mean-square fluctuations (rmsf) as a function of time for residues 480–489 for all three variants: WT (green), B.1.1.7 (blue), and B.1.351 (red). (f) Distance between the Cα atoms of residues 484 and 489 showing large-scale motions of the loop segment. The rmsf and the distance graphs for the replica runs are plotted in Figure S3b,d.

RBD structures at the end of 600 ns simulation for (a) WT, (b) B.1.1.7, and (c) B.1.351. The loop segments consisting of residues 473–489 are highlighted in blue. Mutations in the variants are labeled with red fonts. (d) Structural comparison of the five conformations of each variant, taken from the last 500 ns of the simulation (i.e., one frame every 100 ns). (e) Root-mean-square fluctuations (rmsf) as a function of time for residues 480–489 for all three variants: WT (green), B.1.1.7 (blue), and B.1.351 (red). (f) Distance between the Cα atoms of residues 484 and 489 showing large-scale motions of the loop segment. The rmsf and the distance graphs for the replica runs are plotted in Figure S3b,d.

RBD–ACE2 Interactions in the Variants

To understand the differences in the ACE2 binding, we explored the dynamics of the RBDACE2 complexes for all three variants. The analyses of the interaction pattern between the viral spike protein RBD and the receptor protein ACE2 from the 200 ns of MD simulations show that the B.1.1.7 and B.1.351 mutations have a significant impact on the association of residues in the interfacial region. Figure shows the conformations of each system at 100 ns. The mutated residues are labeled, and the residues across the interface interacting within 3.5 Å of each other are highlighted.
Figure 3

Snapshot of the RBD–ACE2 complex at 100 ns of MD simulation time: (a) WT, (b) B.1.1.7, and (c) B.1.351 variants. Top row: residues interacting within 3.5 Å of each other are highlighted in red for the RBD and blue for the ACE2 protein. The mutated residues in the B.1.1.7 and B.1.351 are labeled. Bottom row: residues forming interfacial hydrogen bonds between the viral spike RBD (green) and the host ACE2 (orange) WT, B.1.1.7, and B.1.351 variants. The highlighted box shows the residue pairs forming hydrogen bonds that only occur in the SA variant.

Snapshot of the RBDACE2 complex at 100 ns of MD simulation time: (a) WT, (b) B.1.1.7, and (c) B.1.351 variants. Top row: residues interacting within 3.5 Å of each other are highlighted in red for the RBD and blue for the ACE2 protein. The mutated residues in the B.1.1.7 and B.1.351 are labeled. Bottom row: residues forming interfacial hydrogen bonds between the viral spike RBD (green) and the host ACE2 (orange) WT, B.1.1.7, and B.1.351 variants. The highlighted box shows the residue pairs forming hydrogen bonds that only occur in the SA variant. To determine how the B.1.1.7 and B.1.351 variants differ from the WT in RBDACE2 bonding, we calculated the number of hydrogen bonds formed during the last 100 ns of the MD simulations. The residue pairs that have significant interaction between the RBD and the ACE2 are identified from the hydrogen bond occupancy rate for each residue pair. Some of the residues contributing to the formation of hydrogen bonds in the RBDACE2 complex for the WT, B.1.1.7, and B.1.351 variants are highlighted in Figure . Figure a–c shows the percentage of time that various interprotein hydrogen bonds existed during the last 100 ns of the simulations for the WT, B.1.1.7, and B.1.351 variants. The H-bonds of the RBDACE2 residue pairs G502K353, T500–D355, Q498–Q42, and N487–Y83 occurred in all three complexes but with different occupancy probabilities. Some H-bonds in the WT become less important or disappear in the B.1.1.7 and B.1.351 variants but new hydrogen bonds S477–E22, T478–E22, and K484–E75 with high occupancy are observed in the B.1.351 variant. H-bonds unique to each system (i.e., present in one and absent in the remaining two) are displayed in Figure d.
Figure 4

Interaction matrix for the residue pairs contributing to interprotein hydrogen bonding: (a) WT, (b) B.1.1.7, and (c) B.1.351 variants. The residue pairs are ordered in the matrices according to the percentage of hydrogen bond occupancy for the WT. The percentage of the hydrogen bonds that are unique to each variant is colored in green. (d) Prominent hydrogen bonds in each variant.

Interaction matrix for the residue pairs contributing to interprotein hydrogen bonding: (a) WT, (b) B.1.1.7, and (c) B.1.351 variants. The residue pairs are ordered in the matrices according to the percentage of hydrogen bond occupancy for the WT. The percentage of the hydrogen bonds that are unique to each variant is colored in green. (d) Prominent hydrogen bonds in each variant. Figure shows that the strong salt-bridge interaction K417–D30 between RBDACE2 is present in both the WT and B.1.1.7 variants but not in the B.1.351 variant with the K417N mutation. In addition, another WT salt-bridge interaction E484–K31 is changed to K484–E75 in the B.1.351 variant. The S477–E22 and T478–E22 H-bond pairs in B.1.351 are especially interesting because they are absent in the WT and B.1.1.7 variants. Both of these H-bonds shown in Figure d are located at the terminal region of the interface (highlighted within the dotted box in Figure c). Overall, the hydrogen bond analysis shows one new H-bond (Y501–K353) in B.1.1.7 and eight new H-bonds (N487–Q23, K484–E75, Q493–K31, F490–K31, S477–E22, A475–Q23, Y505–E37, and T478–E22) in B.1.351. Despite the larger flexibility of the RBD interfacial region of the B.1.351 variant when not complexed with ACE2, the presence of the additional hydrogen bonds at the RBDACE2 interface suggests an enhanced specificity and the formation of a stable complex for this variant. We calculated the binding energies for the RBDACE2 complexes using PRODIGY webserver,[35] which utilizes the interfacial contacts and other properties such as polarity and charge at the interfaces to predict the binding affinity. The binding affinity values calculated for five different frames in the last 20 ns of the 200 ns run are shown in Table S2. These calculations show that the binding affinities are essentially the same in these variants, suggesting that the complexes have similar stabilities. To further explore the interprotein interactions and the stability of complexes, we performed dynamical network analysis.

Dynamic Correlated Motions in the Variants

The bonding interactions described above between the viral RBD and the host ACE2 are crucial in stabilizing the complex. The relative stability of the RBDACE2 complex for the different variants can be elucidated by investigating the conformational flexibility between the RBD and ACE2. We examined this by using a dynamical network analysis method. Dynamical network analysis quantifies connection networks and communities by examining correlated motions in proteins and nucleic acids.[29,36−38] It generates detailed information on the connections of amino acids in the form of communities and gives information about how strongly the amino acids are connected and how much their motion is correlated. Figure shows various amino acid communities in the dynamic network obtained from the last 100 ns of the MD simulation. Amino acids are represented as nodes centered at the Cα, and the correlated motion between the amino acids is represented by the weighted edge (bar) between the nodes. The thickness of the edges represents the strength of the connections between the nodes. For nodes to be in the same community, they need to have a connection for more than 80% of the time.[29]
Figure 5

Dynamic network community analysis for (a) WT, (b) B.1.1.7, and (c) B.1.351 variants from the last 100 ns of the MD simulation trajectory. Communities that span the interface between the RBD and ACE2 are numbered 1–4 and shown in an expanded view for (d) WT (tan, red; 16 interprotein connections), (e) B.1.1.7 (silver, green, red; 18 interprotein connections), and (f) B.1351 (purple, gray, red; 18 interprotein connections).

Dynamic network community analysis for (a) WT, (b) B.1.1.7, and (c) B.1.351 variants from the last 100 ns of the MD simulation trajectory. Communities that span the interface between the RBD and ACE2 are numbered 1–4 and shown in an expanded view for (d) WT (tan, red; 16 interprotein connections), (e) B.1.1.7 (silver, green, red; 18 interprotein connections), and (f) B.1351 (purple, gray, red; 18 interprotein connections). Figure a–c shows various dynamic network communities obtained for all variants, with each community colored differently. To visualize the interprotein interactions between the RBD and the ACE2, the communities that span over both of these proteins are highlighted in the expanded view of the interfacial region shown in Figure d–f. Amino acids present within the same community have highly correlated motions. This means that if a community spreads over the interface to include both the RBD and ACE2, the flexibility of the RBD with respect to the ACE2 is reduced. The amino acids in the RBD and ACE2 that compose each community and their interprotein connections are given in Table S1. The decrease in interfacial flexibility is notable for the B.1.351 variant, which has more and stronger interprotein connections (larger edge weights), compared to that in the WT and the B.1.1.7 variant. From these findings of the number of interprotein connections and the strength of the connections, it appears that the N501Y, E484K, and K417N mutations in the B.1.351 variant allow the formation of a stable RBDACE2 complex. We further explored the conformational motions of these RBDACE2 complexes by using principal component analysis (PCA) with the 200 ns of the MD simulations. PCA is helpful in analyzing the motion of complicated systems with many particles and many internal degrees of freedom. The principal components describe the axes of maximal variance of the distribution of the structure. Eigenvectors represent coordinated motions in the fluctuations in atomic positions during the MD simulation, and the magnitude of the fluctuations of atoms is given by the corresponding eigenvalues. The first few eigenvectors represent the largest motion. Figure S4 shows the range of motion from the principal components (PCs) 1 and 2 for each amino acid for the WT, B.1.17, and B.1.351 variants. The blurrier RBD in Figure S4a implies a greater range of motion for the WT, compared to that of the B.1.351 variant in Figure S4c. The conformational motion of the first three PCA eigenvectors PC1, PC2, and PC3 was projected onto 2D subspaces, as shown in Figure S4d–f. The conformational state of the system in each MD frame is represented by the blue and red dots. These distributions show that the WT complex has a greater conformational range than that of the mutated systems, with the B.1.351 showing more clustered PC1/PC2 and PC1/PC3. These findings are consistent with the results of the hydrogen bond and dynamical network analyses.

Conclusions

The SARS-CoV-2 spike protein is the major surface protein of the virion that is primarily responsible for the virus’s ability to enter the human host through the ACE2 receptor. The interfacial region of the spike RBDACE2 complex plays a major role in the binding of the virus to the host cell. The emergence of mutated variants in the B.1.1.7 and B.1.351 raises concerns about alterations in the interprotein amino binding in this complex as well as in the efficacy of vaccines designed for the WT. Here, we have performed MD simulations and determined changes in the amino acids and their binding at the RBDACE2 interface due to the mutations in three different variants. We find that the RBD interfacial region shows a much larger flexibility in B.1.351 when not complexed with ACE2 but a stronger binding in the complex. The observed changes in the number and strength of the interprotein hydrogen bonds imply an enhanced specificity and binding in the B.1.351 variant, suggesting an optimized flexible interface that allows stronger binding via induced fit mechanism for this variant. Consistent with the stronger interprotein binding, dynamical network analysis and principal component analysis show that the RBDACE2 complex with the B.1.351 variant is less flexible. The question of how the flexibility of the RBD and the subtle changes in the interactions with ACE2 affect the virus’s transmissibility or the vaccine efficacy for a variant is difficult to address but these studies provide information on the molecular interactions of RBDACE2 complexes in different variants, and it can be important for understanding the molecular mechanism of the virus entry into the cell and designing therapeutic interventions. Further studies are needed to understand the full scope of the effects resulting from the mutations or deletions. For example, the mutations may affect trimer formation or trimer stability. In fact, it is recently shown that the D614G mutation enhances the spike protein trimer stability and prevents premature release of S1 subunit.[39] It will be useful to know how the mutations affect the springing up of the RBD from the closed conformation that is shielded with glycans[40,41] or how the mutations in the rest of the spike, including the ones in the furin cleavage site,[42,43] affect the mechanism of virus entry, infectivity, or immune evasion.
  8 in total

1.  Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles.

Authors:  Paulina Kaplonek; Deniz Cizmeci; Stephanie Fischinger; Ai-Ris Collier; Todd Suscovich; Caitlyn Linde; Thomas Broge; Colin Mann; Fatima Amanat; Diana Dayal; Justin Rhee; Michael de St Aubin; Eric J Nilles; Elon R Musk; Anil S Menon; Erica Ollmann Saphire; Florian Krammer; Douglas A Lauffenburger; Dan H Barouch; Galit Alter
Journal:  bioRxiv       Date:  2021-08-31

2.  Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q.

Authors:  Shahzaib Ahamad; Kanipakam Hema; Shahnawaz Ahmad; Vijay Kumar; Dinesh Gupta
Journal:  3 Biotech       Date:  2022-03-03       Impact factor: 2.406

3.  Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions.

Authors:  Mary Hongying Cheng; James M Krieger; Anupam Banerjee; Yufei Xiang; Burak Kaynak; Yi Shi; Moshe Arditi; Ivet Bahar
Journal:  iScience       Date:  2022-02-17

4.  Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.

Authors:  Seonghan Kim; Yi Liu; Zewei Lei; Jeffrey Dicker; Yiwei Cao; X Frank Zhang; Wonpil Im
Journal:  J Chem Theory Comput       Date:  2021-12-03       Impact factor: 6.006

Review 5.  Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development.

Authors:  Eugene M Obeng; Isaac Fianu; Michael K Danquah
Journal:  Nano Today       Date:  2022-08-04       Impact factor: 18.962

6.  All-Atom Simulations of Human ACE2-Spike Protein RBD Complexes for SARS-CoV-2 and Some of its Variants: Nature of Interactions and Free Energy Diagrams for Dissociation of the Protein Complexes.

Authors:  Saheb Dutta; Bhavana Panthi; Amalendu Chandra
Journal:  J Phys Chem B       Date:  2022-07-14       Impact factor: 3.466

7.  Investigation of nonsynonymous mutations in the spike protein of SARS-CoV-2 and its interaction with the ACE2 receptor by molecular docking and MM/GBSA approach.

Authors:  Reem Y Aljindan; Abeer M Al-Subaie; Ahoud I Al-Ohali; Thirumal Kumar D; George Priya Doss C; Balu Kamaraj
Journal:  Comput Biol Med       Date:  2021-07-16       Impact factor: 4.589

8.  Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure.

Authors:  Ozden Hatirnaz Ng; Sezer Akyoney; Ilayda Sahin; Huseyin Okan Soykam; Gunseli Bayram Akcapinar; Ozkan Ozdemir; Derya Dilek Kancagi; Gozde Sir Karakus; Bulut Yurtsever; Ayse Sesin Kocagoz; Ercument Ovali; Ugur Ozbek
Journal:  PLoS One       Date:  2021-12-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.